{"title": "Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing", "doi": "10.1101/2020.03.04.20030916", "citation_id": "2020.03.04.20030916v2", "date": "2020-03-10", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.04.20030916", "abstract": "<p>Corona Virus Disease 2019 (COVID-19) has spread rapidly to more than 70 countries and regions overseas and over 80000 cases have been infected, resulting in more than three thousand deaths. Rapid diagnosis of patients remains a bottleneck in containing the progress of the epidemic. We used automated chemiluminescent immunoassay to detect serum IgM and IgG antibodies to 2019-nCoV of 736 subjects. COVID-19 patients were becoming reactive(positive) for specific antibodies from 7-12 days after the onset of morbidity. Specific IgM and IgG increased with the progression of the disease. The areas under the ROC curves of IgM and IgG were 0.988 and 1.000, respectively. Specific antibody detection has good sensitivity and specificity. Detection of specific antibodies in patients with fever can be a good distinction between COVID-19 and other diseases, so as to be a complement to nucleic acid diagnosis to early diagnosis of suspected cases.</p>", "twitter_description": "Corona Virus Disease 2019 (COVID-19) has spread rapidly to more than 70 countries and regions overseas and over 80000 cases have been infected, resulting in more than three thousand deaths. Rapid diagnosis of patients remains a bottleneck in containing the progress of the epidemic. We used automated chemiluminescent immunoassay to detect serum IgM and IgG antibodies to 2019-nCoV of 736 subjects. COVID-19 patients were becoming reactive(positive) for specific antibodies from 7-12 days after the onset of morbidity. Specific IgM and IgG increased with the progression of the disease. The areas under the ROC curves of IgM and IgG were 0.988 and 1.000, respectively. Specific antibody detection has good sensitivity and specificity. Detection of specific antibodies in patients with fever can be a good distinction between COVID-19 and other diseases, so as to be a complement to nucleic acid diagnosis to early diagnosis of suspected cases.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis study was funded by \u201cthe National Science and Technology Major Project of China (2018ZX10302205)\u201d, \u201cLiaoning Province Natural Science Foundation Project(20180550523)\u201d, \u201cLiaoning Province Central Government's special project to guide local scientific and technological development (2019JH6/10400009)\u201d, \u201cGuangdong Province Major key projects of industrial technology (201902010003)\u201d, \u201cMajor Special Project of Construction Program of China Medical University in 2018(112/3110118034)\u201d and \u201c345 talent project\u201d of Shengjing Hospital of China Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe data used to support the findings of this study are available from the corresponding author upon request.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20030916v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20030916v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20030916v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/10/2020.03.04.20030916.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.04.20030916v2", "access_rights": "restricted", "authors": ["Jin Zhang", "Jianhua Liu", "Na Li", "Yong Liu", "Rui Ye", "Xiaosong Qin", "Rui Zheng"]}